Исследование непосредственной клинической эффективности бролуцизумаба при лечении ВМД

Abstract

Purpose. Analysis of direct clinical efficacy of brolucizumab in choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD). Material and methods. A clinical evaluation of effectiveness of using Beovu® (Novartis Pharma AG, Switzerland) was carried out in 25 patients (25 eyes) with neovascular AMD, mean age old patients was 68 ± 5 years. Dynamic monitoring was carried out using optical coherence tomography: localization and area of neovascular complex, density and thickness of newly formed vessels (angiography mode). 3 monthly injections of Beovu® were performed (at a dose of 6.0 mg/0.05 ml). The observation period was 4 months. Results. After the 1st injection of Beovu®, there was statistically significant decrease in the average indexes of central retinal thickness (CRT) and macular volume (MV) relative to initial. At the same time, an increase in best corrected visual acuity (BCVA) was observed (p = 0.044). A similar trend persists for average values of CRT and MV after each of the 3 injections. It is noteworthy that in all patients, after 3 injections, the minimum values of CRT were achieved – 268 (263; 270) versus 298 (284; 302) µm (p < 0.001). There was also a clear trend towards an increase in BCVA from 0.3 (0.2; 0.45) to 0.6 (0.4; 0.6) in all studied cases (p < 0.001). In 22 of 25 patients, after 1 month, adhesion of the neuro- and pigment epithelium was recorded with complete resorption of subretinal fluid, in 3 patients – after three monthly intravitreal injections of Beovu®, while the subretinal fluid was not recorded in them. Subjectively, all patients noted improvement in quality and contrast of central vision in the operated eyes. Conclusion. After each injection of Beovu®, there was progressive statistically significant reduction in macular area parameters – CRT and MV in combination with an increase in mean BCVA values from 0.3 (0.2; 0.45) initially to 0.6 (0.4; 0.6) by the 4th month of observation. Keywords: vascular endothelial growth factor, anti-VEGF, brolucizumab, Beovu®, age-related macular degeneration, neovascular age-related macular degeneration, wet age-related macular degeneration